IP Library Granted Patent US 10,537,644
Granted Patent B2
US 10,537,644 · App. 15/524,487 · Granted Jan 21, 2020

Covalent linkers in antibody-drug conjugates and methods of making and using the same

Inventors: Chang Jiang Huang (Los Angeles, CA); Jianmin Fang (Palo Alto, CA); Hui Ye (Shandong, CN); Lezhi Zhang (Shandong, CN)
Assignee: RC BIOTECHNOLOGIES, INC.
A61K47/545A61K47/54A61K47/6803A61K47/6811A61K47/6855A61K47/6869A61K47/6889A61P35/00C07K16/2896C07K16/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,537,644
App. No.
15/524,487
Granted
Jan 21, 2020
Kind
B2
Abstract

The present invention provides novel and advantageous compositions having a linker capable of covalently coupling one or more free thiols of an antibody. Specifically, provided herein are the molecular structures, synthetic pathways, coupling mechanisms, and applications thereof as used in an antibody-drug conjugate (ADC).

Claims (24)

1. An antibody-drug conjugate having the following formula:

or a pharmaceutically acceptable salt thereof,

wherein:

L 1 , and L 2 each represent a linker independently selected from C 1 -C 6 alkyls, S, C(═O), and combinations thereof, or can be null;

M represents a linking group of

Q represents an active agent selected from tubulin binders, DNA alkylators, DNA intercalators, enzyme inhibitors, immune modalators, visualization agents, peptides, and nucleotides;

L represents a linker selected from C 1 -C 6 alkyls, S, C(═O), Val-Cit-PAB,

and combinations thereof;

m represents an integer from 0 to 6;

n represents an integer from 0 to 8

A is an antibody or functional fragment thereof

S is a sulfur atom of a thiol group of the targeting moiety; and

each of R 3 and R 4 is

2. The antibody-drug conjugate as claimed in claim 1 , wherein the structure of Formula II is:

3. The antibody-drug conjugate as claimed in claim 1 , wherein the antibody-drug conjugate having the following formula II:

or a pharmaceutically acceptable salt thereof,

Wherein:

A is a targeting moiety;

Q is selected from tubulin binders, DNA alkylators, DNA intercalators, enzyme inhibitors, immune modalators, visualization agents, peptides, and nucleotides;

n represents an integer from 0 to 8.

4. The antibody-drug conjugate as claimed in claim 1 , wherein Q is selected from

5. The antibody-drug conjugate as claimed in claim 1 , wherein the structure of Formula II is:

6. The antibody-drug conjugate as claimed in claim 1 , wherein the structure of Formula II is:

7. The antibody-drug conjugate as claimed in claim 1 , wherein the structure of Formula II is:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2023
From: RC BIOTECHNOLOGIES, INC.
To: REMEGEN CO., LTD.
Reel/Frame 062666/0256 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2017
From: HUANG, CHANG JIANG; FANG, JIANMIN; YE, HUI; ZHANG, LEZHI
To: RC BIOTECHNOLOGIES, INC.
Reel/Frame 042374/0148 →
Continuity (2)
Provisional Application 62205121 · Aug 14, 2015
Related Publication 20180055948A1 · Mar 1, 2018
Cited By (1)
US 12,691,185